Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading on Wednesday. $86.30 million flowed into the stock on the tick-up and $212.66 million flowed out of the stock on the tick-down, for a money net flow of $126.36 million out of the stock. Of all companies tracked, Pfizer had the 8th highest net out-flow for the day. Pfizer traded up $0.25 for the day and closed at $35.19

A number of analysts have recently commented on PFE shares. BMO Capital Markets restated a “buy” rating and set a $39.00 target price (up previously from $37.00) on shares of Pfizer in a report on Thursday, October 19th. Jefferies Group set a $39.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Thursday, October 26th. Berenberg Bank set a $36.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Tuesday, October 31st. UBS Group set a $38.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, November 1st. Finally, Goldman Sachs Group set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, November 1st. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $39.45.

The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $209,760.00, a PE ratio of 10.00, a price-to-earnings-growth ratio of 1.96 and a beta of 0.94.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The business had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. During the same quarter in the previous year, the firm earned $0.47 EPS. Pfizer’s revenue was up .6% on a year-over-year basis. sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be given a $0.34 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.86%. Pfizer’s payout ratio is 38.64%.

Pfizer declared that its Board of Directors has authorized a share buyback program on Monday, December 18th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s board believes its shares are undervalued.

In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the transaction, the insider now owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the transaction, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Pfizer by 2.8% during the 4th quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock valued at $16,398,445,000 after purchasing an additional 12,183,218 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after purchasing an additional 9,239,499 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Pfizer by 11.9% during the 4th quarter. Bank of New York Mellon Corp now owns 70,738,885 shares of the biopharmaceutical company’s stock valued at $2,562,162,000 after acquiring an additional 7,534,957 shares during the period. Geode Capital Management LLC grew its stake in shares of Pfizer by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 63,123,777 shares of the biopharmaceutical company’s stock valued at $2,281,563,000 after acquiring an additional 1,881,570 shares during the period. Finally, Ameriprise Financial Inc. grew its stake in shares of Pfizer by 4.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock valued at $2,136,189,000 after acquiring an additional 2,502,659 shares during the period. 70.06% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Investors Sell Shares of Pfizer (PFE) on Strength (PFE)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2018/02/14/investors-sell-shares-of-pfizer-pfe-on-strength-pfe-3.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.